Amphastar P (AMPH) - Net Assets
Based on the latest financial reports, Amphastar P (AMPH) has net assets worth $788.80 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.63 Billion) and total liabilities ($840.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Amphastar P liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $788.80 Million |
| % of Total Assets | 48.41% |
| Annual Growth Rate | 9.82% |
| 5-Year Change | 77.05% |
| 10-Year Change | 139.57% |
| Growth Volatility | 6.28 |
Amphastar P - Net Assets Trend (2012–2025)
This chart illustrates how Amphastar P's net assets have evolved over time, based on quarterly financial data. Also explore Amphastar P asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Amphastar P (2012–2025)
The table below shows the annual net assets of Amphastar P from 2012 to 2025. For live valuation and market cap data, see AMPH stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $788.80 Million | +7.72% |
| 2024-12-31 | $732.30 Million | +14.53% |
| 2023-12-31 | $639.42 Million | +20.95% |
| 2022-12-31 | $528.66 Million | +18.66% |
| 2021-12-31 | $445.52 Million | -0.71% |
| 2020-12-31 | $448.72 Million | +4.96% |
| 2019-12-31 | $427.53 Million | +17.34% |
| 2018-12-31 | $364.36 Million | +8.01% |
| 2017-12-31 | $337.33 Million | +2.45% |
| 2016-12-31 | $329.25 Million | +11.42% |
| 2015-12-31 | $295.51 Million | +4.84% |
| 2014-12-31 | $281.86 Million | +12.05% |
| 2013-12-31 | $251.54 Million | +7.76% |
| 2012-12-31 | $233.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amphastar P's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 976.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $666.88 Million | 84.54% |
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $-5.31 Million | -0.67% |
| Other Components | $127.23 Million | 16.13% |
| Total Equity | $788.80 Million | 100.00% |
Amphastar P Competitors by Market Cap
The table below lists competitors of Amphastar P ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hartalega Holdings Bhd
KLSE:5168
|
$959.79 Million |
|
Fujian Guanfu Modern Household Wares Co Ltd
SHE:002102
|
$959.99 Million |
|
Daktronics Inc
NASDAQ:DAKT
|
$960.33 Million |
|
Catalyst Metals Ltd
AU:CYL
|
$961.10 Million |
|
Zhejiang Yuejian Intelligent Equipment Co Ltd
SHG:603095
|
$958.81 Million |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
$958.76 Million |
|
Evolv Technologies Holdings Inc
NASDAQ:EVLV
|
$958.65 Million |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
$958.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amphastar P's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 732,298,000 to 788,805,000, a change of 56,507,000 (7.7%).
- Net income of 98,094,000 contributed positively to equity growth.
- Share repurchases of 75,586,000 reduced equity.
- Other comprehensive income increased equity by 3,867,000.
- Other factors increased equity by 30,132,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $98.09 Million | +12.44% |
| Share Repurchases | $75.59 Million | -9.58% |
| Other Comprehensive Income | $3.87 Million | +0.49% |
| Other Changes | $30.13 Million | +3.82% |
| Total Change | $- | 7.72% |
Book Value vs Market Value Analysis
This analysis compares Amphastar P's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.75x to 1.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $29.18 | $21.88 | x |
| 2013-12-31 | $31.44 | $21.88 | x |
| 2014-12-31 | $6.72 | $21.88 | x |
| 2015-12-31 | $6.57 | $21.88 | x |
| 2016-12-31 | $6.93 | $21.88 | x |
| 2017-12-31 | $6.97 | $21.88 | x |
| 2018-12-31 | $7.17 | $21.88 | x |
| 2019-12-31 | $7.64 | $21.88 | x |
| 2020-12-31 | $8.19 | $21.88 | x |
| 2021-12-31 | $8.95 | $21.88 | x |
| 2022-12-31 | $10.08 | $21.88 | x |
| 2023-12-31 | $12.06 | $21.88 | x |
| 2024-12-31 | $14.07 | $21.88 | x |
| 2025-12-31 | $16.36 | $21.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amphastar P utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.44%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.63%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.07x
- Recent ROE (12.44%) is above the historical average (7.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 7.75% | 8.86% | 0.64x | 1.36x | $-5.25 Million |
| 2013 | 4.72% | 5.16% | 0.68x | 1.35x | $-13.29 Million |
| 2014 | -3.80% | -5.08% | 0.54x | 1.38x | $-38.88 Million |
| 2015 | -0.94% | -1.11% | 0.64x | 1.32x | $-32.34 Million |
| 2016 | 3.20% | 4.13% | 0.60x | 1.30x | $-22.39 Million |
| 2017 | 1.34% | 1.88% | 0.53x | 1.35x | $-29.22 Million |
| 2018 | -1.73% | -1.95% | 0.57x | 1.54x | $-38.98 Million |
| 2019 | 12.83% | 15.18% | 0.55x | 1.54x | $10.80 Million |
| 2020 | 0.35% | 0.40% | 0.55x | 1.57x | $-38.83 Million |
| 2021 | 13.94% | 14.19% | 0.65x | 1.51x | $17.56 Million |
| 2022 | 17.29% | 18.31% | 0.67x | 1.40x | $38.52 Million |
| 2023 | 21.51% | 21.34% | 0.43x | 2.37x | $73.60 Million |
| 2024 | 21.78% | 21.79% | 0.46x | 2.15x | $86.29 Million |
| 2025 | 12.44% | 13.63% | 0.44x | 2.07x | $19.21 Million |
Industry Comparison
This section compares Amphastar P's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $191,301,027
- Average return on equity (ROE) among peers: -54.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amphastar P (AMPH) | $788.80 Million | 7.75% | 1.07x | $959.02 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more